Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 (n =3424) - Harbeck, N; Kates, RE (Cancer Res, 2000)
et al.